A new model outperforming RPA and DS-GPA scores for individualized survival prediction of patients following whole brain irradiation for brain metastasis

Marchand-Crety, Charles; Riverain, J.; Drouet, Youenn; Felici, F.; Jeandidier, C.L.; Thariat, Juliette; Servagi-Vernat, S.

doi:10.1016/j.canrad.2021.02.002

Cited by 2 publications

(1 citation statement)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A French study from 2021 analyzed 173 patients with multiple brain metastases. The aim was also to design a prognostic scale to identify patients who were not candidates for WBRT (15). The multivariate study shared with the RPA and GPA scales the impact of extracranial metastases on survival (p < 0.005), differing with our results.…”

Section: Discussioncontrasting

confidence: 69%

A new updated prognostic index for patients with brain metastases (BM) treated with palliative whole brain radiotherapy (WBRT) in the era of precision oncology. METASNCore project

Flores-Paco,

Vargas,

Guevara

et al. 2024

Preprint

View full text Add to dashboard Cite

Introduction Palliative WBRT is the main treatment for multiple BM. Recent studies report no benefit in survival after WBRT compared to palliative supportive care in patients (pts) with poor prognosis. A new era of systemic treatment strategies based on targeted therapies are improving the prognosis of patients with BM. The purpose of this study is to develop a prognostic score in palliative pts with BM who undergo WBRT in this new setting. Methods 239 pts with BM who received palliative WBRT between 2013–2022 in our center were analyzed retrospectively. The score was designed according to the value of the β coefficient of each variable with statistical significance in the multivariate model using Cox regression. Once the score was established, a comparison was performed according to Kaplan-Meier and was analyzed by log-rank test. Results: 149 pts (62.3%) were male and median (m) age was 60 years. 139 (58,2%) were lung cancer and 35 (14,6%) breast cancer. All patients received 30Gys in 10 sessions. m overall survival (OS) was 3,74 months (ms). 37 pts (15,5%) had a specific target mutation. We found that 62 pts were in group < 4 points with mOS 6,89ms (CI 95% 3,18 − 10,62), 84 in group 4–7 points with mOS 4,01ms (CI 95% 3,40 − 4,62) and 92 pts in group > 7 points with mOS 2,72ms (CI 95% 1,93 − 3,52) (p < 0,001). Conclusions: METASNCore items are associated with OS and they could be useful to select palliative pts to receive WBRT. More studies are necessary to corroborate our findings.

show abstract

Section: Discussioncontrasting

confidence: 69%